Wesana Health has announced positive results from an animal study conducted by an independent global laboratory services provider in a validated model of depression.
Results of the study showed that administration of imipramine given three weeks following a psilocybin loading dose provided an additional 39% further improvement in depressive behaviours from that of psilocybin loading dose alone. Furthermore, the second administration of imipramine given four weeks after a psilocybin loading dose provided an even greater reduction (45%) in depressive behaviours.
Category Press Release
Published in GlobeNewswire
Companies Featured
Wesana HealthWesana Health is a data-driven life science company focused on the delivery and development of therapies, including psychedelics, to treat traumatic brain injury (TBI), migraines, depression and anxiety.